CR9918A - Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina - Google Patents

Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina

Info

Publication number
CR9918A
CR9918A CR9918A CR9918A CR9918A CR 9918 A CR9918 A CR 9918A CR 9918 A CR9918 A CR 9918A CR 9918 A CR9918 A CR 9918A CR 9918 A CR9918 A CR 9918A
Authority
CR
Costa Rica
Prior art keywords
antigonist
pirazolo
pyrimidinyl
alpha
derivatives
Prior art date
Application number
CR9918A
Other languages
English (en)
Inventor
Frank Hossner
Original Assignee
Neurocrine Biosciences Inc
Bayer Cropsciense Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc, Bayer Cropsciense Ag filed Critical Neurocrine Biosciences Inc
Publication of CR9918A publication Critical patent/CR9918A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR9918A 2005-09-30 2008-04-23 Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina CR9918A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0519957.5A GB0519957D0 (en) 2005-09-30 2005-09-30 Chemical compound

Publications (1)

Publication Number Publication Date
CR9918A true CR9918A (es) 2009-02-03

Family

ID=35395069

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9918A CR9918A (es) 2005-09-30 2008-04-23 Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina

Country Status (21)

Country Link
US (1) US7879862B2 (es)
EP (2) EP1802627B1 (es)
JP (2) JP4901744B2 (es)
KR (2) KR20070088621A (es)
CN (1) CN101273043B (es)
AR (2) AR051461A1 (es)
AU (2) AU2005295353B2 (es)
BR (1) BRPI0616767A2 (es)
CA (2) CA2584567C (es)
CR (1) CR9918A (es)
EA (1) EA200801000A1 (es)
GB (1) GB0519957D0 (es)
IL (1) IL190225A0 (es)
MA (1) MA29850B1 (es)
NO (2) NO20072541L (es)
NZ (1) NZ554082A (es)
PE (2) PE20060586A1 (es)
RU (1) RU2007118683A (es)
TW (2) TW200626599A (es)
UA (1) UA92756C2 (es)
WO (2) WO2006044958A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
AR046967A1 (es) * 2003-12-22 2006-01-04 Sb Pharmco Inc Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en) 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101932583A (zh) 2007-12-19 2010-12-29 沃泰克斯药物股份有限公司 用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类
BRPI0911659B8 (pt) 2008-04-15 2021-05-25 Eisai R&D Man Co Ltd composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
US20140309226A1 (en) 2011-11-16 2014-10-16 Array Biopharma Inc. Piperidinyl-substituted cyclic ureas as gpr119 modulators
WO2013160317A2 (en) * 2012-04-23 2013-10-31 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
RU2718918C2 (ru) 2014-01-21 2020-04-15 Ньюрокрайн Байосайенсиз, Инк. Антагонисты рецептора cfr1 для лечения врожденной гиперплазии коры надпочечников
CN106061975B (zh) * 2014-01-22 2019-09-24 库洛维公司 作为抗病毒化合物的吡唑并[1,5-a]嘧啶
KR102662065B1 (ko) 2017-02-17 2024-05-07 트레베나, 인코포레이티드. 7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
BR112021010847A2 (pt) 2018-12-07 2021-09-08 Neurocrine Biosciences Inc. Antagonista de receptor de crf1, formulações farmacêuticas e formas sólidas das mesmas para o tratamento de hiperplasia adrenal congênita
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
EP4076448A4 (en) 2019-12-20 2024-03-27 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
EP4236939A4 (en) * 2020-10-27 2024-08-07 Trevena, Inc. Crystalline and amorphous forms of a delta-opioid modulator
EP4333841A1 (en) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
EP0714898B1 (en) 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
DE880523T1 (de) 1996-02-07 2002-07-04 Janssen Pharmaceutica N.V., Beerse Pyrazolopyrimidine als crf rezeptor-antagonisten
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
SK286461B6 (sk) * 1996-07-24 2008-10-07 Bristol-Myers Squibb Pharma Company [1,5-a]-Pyrazolo-1,3,5-triazíny, ich použitie a farmaceutické kompozície na ich báze
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
ES2273369T3 (es) 1996-08-28 2007-05-01 Pfizer Inc. Derivados 6,5 heterobiciclicos sustituidos.
EP1049699B1 (en) 1998-01-28 2004-04-21 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as crf antagonists
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
EP1149835A4 (en) 1999-01-29 2002-08-21 Sumitomo Chemical Co AGENTS FOR INHIBITATION OF FAT
AU4203500A (en) * 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
EP1218381B1 (en) * 1999-09-30 2006-12-06 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES
JP2003510325A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション ある種のアルキレンジアミン−置換ピラゾロ[1,5−a]−1,5−ピリミジン及びピラゾロ[1,5−a]−1,3,5−トリアジン
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
CA2446514A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
US7462622B2 (en) * 2001-06-12 2008-12-09 Glaxo Group Limited Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
DE602004005960T2 (de) * 2003-01-16 2008-01-17 Sb Pharmco Puerto Rico Inc. Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
JP2007515474A (ja) * 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Crf受容体アンタゴニストおよびそれらに関連する方法
AR046967A1 (es) * 2003-12-22 2006-01-04 Sb Pharmco Inc Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
DE602005014375D1 (de) * 2004-10-19 2009-06-18 Neurocrine Biosciences Inc Crf-rezeptor-antagonisten und zugehörige verfahren
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
CA2624699A1 (en) 2007-04-12
CA2584567A1 (en) 2006-04-27
AR051461A1 (es) 2007-01-17
AU2005295353A1 (en) 2006-04-27
NO20081941L (no) 2008-04-23
WO2007039264A1 (en) 2007-04-12
PE20060586A1 (es) 2006-09-20
JP2009510004A (ja) 2009-03-12
EP1934222A1 (en) 2008-06-25
JP4901744B2 (ja) 2012-03-21
JP2008517067A (ja) 2008-05-22
US7879862B2 (en) 2011-02-01
EA200801000A1 (ru) 2009-02-27
AR056104A1 (es) 2007-09-19
KR20080063760A (ko) 2008-07-07
US20080194589A1 (en) 2008-08-14
RU2007118683A (ru) 2008-11-27
KR20070088621A (ko) 2007-08-29
EP1802627B1 (en) 2012-08-29
CA2584567C (en) 2013-04-30
PE20070845A1 (es) 2007-08-25
AU2006298995B2 (en) 2012-06-14
EP1802627A1 (en) 2007-07-04
UA92756C2 (ru) 2010-12-10
EP1934222B1 (en) 2012-07-25
MA29850B1 (fr) 2008-10-03
TW200745121A (en) 2007-12-16
TW200626599A (en) 2006-08-01
WO2006044958A1 (en) 2006-04-27
AU2006298995A1 (en) 2007-04-12
WO2006044958A8 (en) 2006-06-08
AU2005295353B2 (en) 2012-01-12
CN101273043A (zh) 2008-09-24
GB0519957D0 (en) 2005-11-09
NZ554082A (en) 2010-12-24
CN101273043B (zh) 2011-08-03
IL190225A0 (en) 2009-09-22
BRPI0616767A2 (pt) 2011-06-28
NO20072541L (no) 2007-06-25

Similar Documents

Publication Publication Date Title
CR9918A (es) Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina
MA28824B1 (fr) Derives de pyrimidine
MA28813B1 (fr) Derives de pyrimidine
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
BRPI0716936A2 (pt) derivados de adenosina como antigonistas de receptor de a2a
NL2000323A1 (nl) Pyrimidine-derivaten.
CU23886B1 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
EP2154967A4 (en) Pyrimidine derivatives
ATE481409T1 (de) Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
DOP2007000068A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
DK1995242T3 (da) Hidtil ukendt 1,2,3,4-tetrahydroquinoxalinderivat med glucocorticoidreceptorbindingsaktivitet.
ZA200708187B (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-D]pyrimidine derivatives
CR20130209A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
GB0525080D0 (en) Pyrimidine derivatives
GB0525083D0 (en) Pyrimidine derivatives
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE538130T1 (de) Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
DE602006010508D1 (de) Substituierte triazolderivate als oxytocinantagonisten
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
PT1355639E (pt) Derivados de carboestirilo substituidos como agonistas do subtipo de receptores 5-ht1a
ATE449080T1 (de) 4-phenyl-6-substituierte pyrimidin-2- carbonitrilderivate
ATE513817T1 (de) Pyrimidinderivate und ihre verwendung als pestizide
GB0525081D0 (en) Pyrimidine derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)